Elevance Health (NYSE:ELV) Raised to "Buy" at Argus

Elevance Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Argus upgraded Elevance Health to “Buy” from “Hold” and set a $510 price target, implying 17.38% upside from the current share price.
  • Analyst sentiment is broadly positive: 16 analysts rate ELV “Buy” and seven “Hold,” giving it a “Moderate Buy” consensus and an average price target of $458.91.
  • Elevance reported quarterly EPS of $6.99, beating the $4.71 estimate, while revenue of $50.44 billion also exceeded expectations.
  • MarketBeat previews the top five stocks to own by December 1st.

Elevance Health (NYSE:ELV - Get Free Report) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating in a report released on Wednesday, MarketBeat Ratings reports. The firm currently has a $510.00 price objective on the stock. Argus's target price indicates a potential upside of 17.38% from the stock's current price.

Several other equities research analysts also recently issued reports on ELV. Wall Street Zen raised Elevance Health from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Elevance Health in a research note on Wednesday, November 11th. UBS Group upped their target price on Elevance Health from $460.00 to $523.00 and gave the company a "buy" rating in a report on Thursday, October 22nd. Royal Bank Of Canada increased their price target on shares of Elevance Health from $424.00 to $455.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 22nd. Finally, The Goldman Sachs Group restated a "neutral" rating and set a $451.00 price target on shares of Elevance Health in a report on Friday, October 23rd. Sixteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health presently has a consensus rating of "Moderate Buy" and an average price target of $458.91.

Read Our Latest Research Report on ELV

Elevance Health Price Performance

Shares of NYSE:ELV opened at $434.47 on Wednesday. The company's fifty day moving average is $416.83 and its two-hundred day moving average is $376.16. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. Elevance Health has a 12-month low of $274.84 and a 12-month high of $450.69. The company has a market cap of $93.87 billion, a P/E ratio of 18.53, a price-to-earnings-growth ratio of 2.13 and a beta of 0.63.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.71 by $2.28. The company had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company's revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.03 earnings per share. Equities analysts expect that Elevance Health will post 29.15 earnings per share for the current fiscal year.

Insider Transactions at Elevance Health

In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the company's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president directly owned 14,849 shares of the company's stock, valued at $6,533,560. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of the firm's stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company's stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELV. Activest Wealth Management increased its stake in shares of Elevance Health by 146.2% during the 3rd quarter. Activest Wealth Management now owns 64 shares of the company's stock worth $25,000 after purchasing an additional 38 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Elevance Health in the 3rd quarter valued at $26,000. Kilter Group LLC acquired a new stake in shares of Elevance Health in the 2nd quarter valued at $28,000. WealthCollab LLC boosted its holdings in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company's stock worth $27,000 after purchasing an additional 27 shares in the last quarter. Finally, Elevation Wealth Partners LLC boosted its holdings in Elevance Health by 600.0% in the second quarter. Elevation Wealth Partners LLC now owns 105 shares of the company's stock worth $41,000 after purchasing an additional 90 shares in the last quarter. Institutional investors own 89.24% of the company's stock.

About Elevance Health

(Get Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Further Reading

Analyst Recommendations for Elevance Health (NYSE:ELV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elevance Health Right Now?

Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines